The main aim of this clinical study is to investigate whether the blood concentration of methotrexate changes when AZD9056 is co- administered together with methotrexate.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
Tablets for oral use. 400 mg once daily for 7 days
Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
Pharmacokinetics of AZD9056 and Methotrexate
Time frame: Pharmacokinetic samples for Methotrexate taken at baseline and and at steady state.Pharmacokinetc samples for AZD9056 taken at steady state
Pharmacokinetics of AZD9056 and 7-OH Methotrexate
Time frame: Pharmacokinetics samples for 7-OH Methotrexate taken at baseline and and at steady state.Pharmacokinetc samples for AZD9056 taken at steady state
Safety and tolerability (Physical examination, vital signs, electrocardiogram (ECG), safety laboratory,adverse events.)
Time frame: During the whole study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.